LONDON and SONGDO,
South Korea, May 21, 2020
/PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Samsung
Biologics (207940.KS) have entered into a partnership to provide
GSK with additional capacity to manufacture and supply GSK's
innovative biopharmaceutical therapies.
Under the terms of the agreement, Samsung Biologics will provide
GSK with additional capacity for large-scale biopharmaceutical
product manufacturing. This capacity will be flexible depending on
GSK's future needs and will supplement GSK's existing manufacturing
network.
Regis Simard, President,
Pharmaceuticals Supply Chain, GSK, said, "Today's agreement with
Samsung Biologics complements and reinforces our existing
world-class pharmaceutical manufacturing capability and will help
ensure we can continue to deliver the transformative medicines that
patients need."
"We are very proud and excited to announce this long-term
agreement with GSK," said Dr. Tae Han
Kim, CEO of Samsung Biologics. "Samsung Biologics entered
the biopharma industry with the goal to help our clients bring
valuable biological medicines to patients faster. We are thrilled
to partner with GSK, a company who shares the vision."
The agreement is worth more than $231 million USD over the next eight years. It will
initially cover commercial production of Benlysta (belimumab), with
technology transfer starting in 2020 and first commercial supply
expected in 2022. The intention is to expand to additional
specialty-care products in the future.
About Samsung Biologics Co. Ltd.
Samsung Biologics is a fully integrated CDMO offering
state-of-the-art contract development, manufacturing, and
analytical testing services. With a proven regulatory approvals
record, the largest capacity, and the fastest throughput, Samsung
Biologics is an award-winning partner of choice and is uniquely
able to support the development and manufacturing of biologics
products at every stage of the process while meeting the evolving
needs of biopharmaceutical companies worldwide. For more
information, visit www.samsungbiologics.com.
About GlaxoSmithKline
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information, please visit www.gsk.com
Press Contact:
Samsung Biologics | Claire Kim
cair.kim@samsung.com
GSK | Tim Foley:
tim.x.foley@gsk.com
View original
content:http://www.prnewswire.com/news-releases/gsk-partners-with-samsung-biologics-to-secure-additional-manufacturing-capacity-for-innovative-biopharmaceutical-portfolio-301064072.html
SOURCE Samsung Biologics